# RAD51 andXRCC3 Polymorphisms Are Associated with Increased Risk of Prostate Cancer

Authors: Maria Nowacka-Zawisza; Agata Raszkiewicz; Tomasz Kwasiborski; Ewa Forma; Magdalena Bryś; Waldemar Różański; Wanda M. Krajewska
Journal: Journal of Oncology
 (2019)

---

## Abstract

Genetic polymorphisms in DNA repair genes may affect DNA repair efficiency and may contribute to the risk of developing cancer. The aim of our study was to investigate single nucleotide polymorphisms (SNPs) inRAD51 (rs2619679, rs2928140, and rs5030789) andXRCC3(rs1799796) involved in DNA double-strand break repair and their relationship to prostate cancer. The study group included 99 men diagnosed with prostate cancer and 205 cancer-free controls. SNP genotyping was performed using the PCR-RFLP method. A significant association was detected betweenRAD51 rs5030789 polymorphism andXRCC3 rs1799796 polymorphism and an increased risk of prostate cancer. Our results indicate thatRAD51 andXRCC3 polymorphism may contribute to prostate cancer.


---

## Body

## 1. Introduction

Prostate cancer is the second most commonly occurring cancer and the fifth leading cause of cancer death in men with an estimated 1.3 million new cases and 359.000 associated deaths worldwide in 2018. It is the most frequently diagnosed cancer among men in over one-half of the countries of the world [1, 2]. Prostate cancer is characterized by the highest dynamic of increase in the last decade, and in 2016, for the first time, it became the most common cancer among men in Poland [3]. This cancer is very rarely manifested before the age of 50, and more than half of patients at the time of diagnosis are at least 70 years old. Age-adjusted incidence rates of prostate cancer increased dramatically and this is largely because of the increased availability of screening for specific prostate antigen (PSA) in men without symptoms of the desease. PSA screening offers a potential benefit of reducing the chance of death from prostate cancer. However, the value of PSA screening is moderate. An increase in PSA over 4 ng/ml suggests cancer, but nearly 25% of men with elevated levels of PSA do not have cancer, and nearly 20% of patients with prostate cancer have normal serum PSA. Elevated PSA levels may be also associated with benign conditions such as inflammation and benign prostatic hypertrophy and procedures such as bladder catheterization, transrectal ultrasound, gland biopsy, cystoscopy, and transurethral endoscopy. The search for markers other than PSA, allowing for early diagnosis and prognosis of prostate cancer, seems to be justified [3, 4]. The factors associated with an increased risk of prostate cancer include family burden, race, ethnicity, obesity, high fat diet, smoking, and exposure to androgens [2]. Germline and somatic mutations appeared to be well-established risk factors for primary and metastaic prostate cancer. In addition, genome-wide association studies (GWAS) have identified approximately 170 SNPs associated with the development of prostate cancer. Pathogenic variants of high and moderate penetrance genes, such asBRCA1 andBRCA2, mismatch repair genes, andHOXB13 confer modest to high lifetime risk of prostate cancer. Some, such asBRCA2, have emerging clinical relevance in the treatment and screening for prostate cancer [5–8].The process of tumorigenesis occurs in the absence of efficient DNA repair systems and this may, among others, result from genetic variations in the genes involved in them. The most deleterious form of DNA damage is the double-strand break (DSB). In order to maintain genomic stability, double-strand breaks must be repaired by homologous recombination (HR) or nonhomologous end joining (NHEJ). Germline and somatic mutations in genes that promote homology-directed repair, especiallyBRCA1 andBRCA2, are frequently observed in several cancers, in particular, breast and ovary, but also prostate and other cancers. The critical biochemical function of BRCA2 in homology-directed repair is to promote RAD51 filament assembly onto ssDNA that arises from end resection. BRCA2 directly interacts with RAD51 at multiple sites to facilitate RAD51 filament assembly. BRCA2 is shown to regulate both the intracellular localization and DNA-binding ability of RAD51. Loss of these controls may be a key event leading to genomic instability and tumorigenesis [9, 10]. The humanRAD51, located on chromosome 15q15.1, plays a crucial role in DNA double-strand break repair [11]. The protein encoded by this gene is a member of RAD51 protein family. RAD51 family members are highly similar to bacterial RecA andSaccharomyces cerevisiae Rad51 and are known to be involved in the homologous recombination and repair of DNA. RAD51 binds to single- and double-stranded DNA and exhibits DNA-dependent ATPase activity. RAD51 catalyzes the recognition of homology and strand exchange between homologous DNA partners to form a joint molecule between a processed DNA break and the repair template. RAD51 binds to single-stranded DNA in an ATP-dependent manner to form nucleoprotein filaments which are essential for the homology search and strand exchange. RAD51 plays a role in regulating mitochondrial DNA copy number under conditions of oxidative stress in the presence of RAD51C and XRCC3 and is also involved in interstrand cross-link repair. At the site of DNA damage nuclear foci containing BRCA1, BRCA2, and RAD51, together with other proteins engaged in homologous recombination, are forming. The protein that binds to RAD51 is XRCC3. This combination facilitates formation of the nucleoprotein filament that represents primary vector for both homologous and heterologous recombination [12–16].As we have previously shown the rs1801320 polymorphism inRAD51 may contribute to prostate cancer susceptibility in Poland [17]. The purpose of the presented work was to investigate further selected single nucleotide polymorphisms (SNPs), i.e., rs2619679, rs2928140, and rs5030789 inRAD51 and rs1799796 inRAD51paralogXRCC3 and their relationship to prostate cancer.


## 2. Material and Methods

### 2.1. Patients

The study group included 99 men with prostate adenocarcinoma and 205 sex- and age-matched cancer-free subjects with low (<4 ng/ml) levels of PSA as a control group. Peripheral blood samples from the patients with prostate adenocarcinoma were obtained from the Department of Urology 2, Medical University of Lodz, Poland. Peripheral blood samples from the control group were obtained from the Urological Department of the Provincial M. Sklodowska-Curie Hospital in Zgierz, Poland. Table1 presents clinicopathological characteristics of patients and the control group.Table 1
Clinicopathological characteristics of studied material.
Parameter Control group (n=205)  Age Range 43 - 84 Mean ± SD 63.33 ± 9.28 Median 64  PSAT (ng/ml) Range 0.004 – 3.94 Mean ± SD 1.09 ± 0.88 Median 0.95  Patients with prostate cancer (n=99)  Age Range 49 - 85 Mean ± SD 70.38 ± 8.63 Median 71  PSAT (ng/ml) Range 4.01 – 1489.00 Mean ± SD 59.17 ± 184.59 Median 9.22  Free/total PSA (F/T PSA) Range 0.04-0.79 Mean ± SD 0.19±0.15 Median 0.16 < 0.16 48 ≥ 0.16 51  PSA Density (PSAD, ng/ml) Range 0.07-56.4 Mean ± SD 2.57±8.44 Median 0.28 < 0.28 49 ≥ 0.28 50  Prostate volume (ml) Range 20.7-191 Mean ± SD 59.5±39.0 Median 48.2 < 48 46 ≥ 48 53  Gleason score < 7 28 ≥ 7 71  Cancer stage T1-T2 58 T3-T4 41


### 2.2. DNA Isolation

DNA from peripheral blood was isolated by phenol extraction [18] or using AxyPrep Blood Genomic DNA Miniprep Kit (Axygen Biosciences) and stored in -70°C. DNA preparations were subjected to spectrophotometric analysis (Biophotometer Eppendorf AG, Germany) by measuring absorbance at 260 nm and 280 nm to determine the quantity and quality of the isolated nucleic acid. The A260/A280 ratio was in the range 1.8-2.1.


### 2.3. Genotyping

Single nucleotide polymorphism (SNP) was determined by PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism). Tested SNPs are shown in the Table2.Table 2
Polymorphic sites inRAD51 and XRCC3 (according to NCBI).
Gene SNP Other names Chromosome SNP position RAD51 rs2619679 g.3879T>A 15: 40694039 Promoter c.-1285T>A rs2928140 g.7995G>C, 15: 40698155 Intron 1 c.-2-602G>C rs5030789 g.3997A>G, 15: 40694157 Promoter c.-1167A>G  XRCC3 rs1799796 g.20897A>G 14: 103699590 Intron 7 c.562A>GThe primers for studied SNPs were as follows: (F) 5′-CCGTGCAGGCCTTATATGAT-3′ and (R) 5′-AGATAAACCTGGCCAACGTG-3′ for rs2619679; (F) 5′-GCTTCTGGCTATTTTCAAGT-3′ and (R) 5′-TGAGGCAGGTAAATGGCTTC-3′ for rs2928140; (F) 5′-CCGTGCAGGCCTTATATGAT-3′ and (R) 5′-AGATAAACCTGGCCAACGTG-3′ for rs5030789; (F) 5′-CCGCATCCTGGCTAAAAATA-3′ and (R) 5′-CAGAGTATGGGCACTGTGAGC-3′ for rs1799796. The primers were synthesized at Sigma-Aldrich®. The polymerase chain reaction (PCR) was performed in an Applied Biosystems® 2720 thermocycler in total volume of 10μl. The reaction mixture contained 10 ng of genomic DNA; 0.2 μmoles of primers (F) and (R); 3 HOT FIREPol® units of DNA polymerase (5 U/ml); 1 mM GeneAmp dNTPmix (10 mM); 2.5 mM magnesium chloride (25 mM); and 1 x Solis BioDyne buffer B1 (10x concentrated). The components of the PCR reaction mixture were from Solis BioDyne (Estonia) and Applied Biosystem (USA).The temperature-time profile of PCR was as follows: Pre-PCR: 95°C for 12 min; PCR (30 cycles): 95°C for 0.5 min, 63°C (rs2928140) or 64°C (for rs2619679 and rs1799796) or 65°C (rs5030789) for 0.5 min, 72°C for 1 min; Post-PCR at 72°C for 5min.The amplification products were digested with restriction enzymes:HinfI (rs2619679),EarI (rs2928140),NlaIII (rs5030789), orAluI (rs1799796) at 37°C for 16 hours. Enzyme inactivation lasted 20 minutes at 65°C forEarI and at 80°C forHinfI,NlaIII, andAluI. The enzymes came from New England BioLabs Inc. DNA fragments were separated in a 3% agarose gel with ethidium bromide for UV visualization. Electrophoresis was performed in 1x TBE buffer (10x TBE: 89 mM Tris, 89 mM boric acid, 2 M EDTA pH 8.0) and 100V. Examples of the obtained restriction patterns are shown in Figure 1.Figure 1
PCR-RFLP genotyping of (a)RAD51 rs2619679 polymorphism; (b)RAD51 rs2928140 polymorphism; (c)RAD51 rs5030789 polymorphism; (d)XRCC3 rs1799796 polymorphism.
(a) (b) (c) (d)


### 2.4. Statistical Analysis

The compatibility of the genotype distribution with the Hardy-Weinberg law in the control group and in study group was checked by theχ2 test. Significance of differences between the distribution of genotypes/alleles in the control and study group was assessed by the χ2 test. The risk of comorbidity of genotypes/alleles with the disease was assessed based on odds ratio (OR) together with a 95% confidence interval. All results were considered statistically significant atp values <0.05. Statistical calculations were made using spreadsheets available on the websites: quantpsy.org/chisq/chisq.htm and vassarstats.net/odds2x2.html.


## 2.1. Patients

The study group included 99 men with prostate adenocarcinoma and 205 sex- and age-matched cancer-free subjects with low (<4 ng/ml) levels of PSA as a control group. Peripheral blood samples from the patients with prostate adenocarcinoma were obtained from the Department of Urology 2, Medical University of Lodz, Poland. Peripheral blood samples from the control group were obtained from the Urological Department of the Provincial M. Sklodowska-Curie Hospital in Zgierz, Poland. Table1 presents clinicopathological characteristics of patients and the control group.Table 1
Clinicopathological characteristics of studied material.
Parameter Control group (n=205)  Age Range 43 - 84 Mean ± SD 63.33 ± 9.28 Median 64  PSAT (ng/ml) Range 0.004 – 3.94 Mean ± SD 1.09 ± 0.88 Median 0.95  Patients with prostate cancer (n=99)  Age Range 49 - 85 Mean ± SD 70.38 ± 8.63 Median 71  PSAT (ng/ml) Range 4.01 – 1489.00 Mean ± SD 59.17 ± 184.59 Median 9.22  Free/total PSA (F/T PSA) Range 0.04-0.79 Mean ± SD 0.19±0.15 Median 0.16 < 0.16 48 ≥ 0.16 51  PSA Density (PSAD, ng/ml) Range 0.07-56.4 Mean ± SD 2.57±8.44 Median 0.28 < 0.28 49 ≥ 0.28 50  Prostate volume (ml) Range 20.7-191 Mean ± SD 59.5±39.0 Median 48.2 < 48 46 ≥ 48 53  Gleason score < 7 28 ≥ 7 71  Cancer stage T1-T2 58 T3-T4 41


## 2.2. DNA Isolation

DNA from peripheral blood was isolated by phenol extraction [18] or using AxyPrep Blood Genomic DNA Miniprep Kit (Axygen Biosciences) and stored in -70°C. DNA preparations were subjected to spectrophotometric analysis (Biophotometer Eppendorf AG, Germany) by measuring absorbance at 260 nm and 280 nm to determine the quantity and quality of the isolated nucleic acid. The A260/A280 ratio was in the range 1.8-2.1.


## 2.3. Genotyping

Single nucleotide polymorphism (SNP) was determined by PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism). Tested SNPs are shown in the Table2.Table 2
Polymorphic sites inRAD51 and XRCC3 (according to NCBI).
Gene SNP Other names Chromosome SNP position RAD51 rs2619679 g.3879T>A 15: 40694039 Promoter c.-1285T>A rs2928140 g.7995G>C, 15: 40698155 Intron 1 c.-2-602G>C rs5030789 g.3997A>G, 15: 40694157 Promoter c.-1167A>G  XRCC3 rs1799796 g.20897A>G 14: 103699590 Intron 7 c.562A>GThe primers for studied SNPs were as follows: (F) 5′-CCGTGCAGGCCTTATATGAT-3′ and (R) 5′-AGATAAACCTGGCCAACGTG-3′ for rs2619679; (F) 5′-GCTTCTGGCTATTTTCAAGT-3′ and (R) 5′-TGAGGCAGGTAAATGGCTTC-3′ for rs2928140; (F) 5′-CCGTGCAGGCCTTATATGAT-3′ and (R) 5′-AGATAAACCTGGCCAACGTG-3′ for rs5030789; (F) 5′-CCGCATCCTGGCTAAAAATA-3′ and (R) 5′-CAGAGTATGGGCACTGTGAGC-3′ for rs1799796. The primers were synthesized at Sigma-Aldrich®. The polymerase chain reaction (PCR) was performed in an Applied Biosystems® 2720 thermocycler in total volume of 10μl. The reaction mixture contained 10 ng of genomic DNA; 0.2 μmoles of primers (F) and (R); 3 HOT FIREPol® units of DNA polymerase (5 U/ml); 1 mM GeneAmp dNTPmix (10 mM); 2.5 mM magnesium chloride (25 mM); and 1 x Solis BioDyne buffer B1 (10x concentrated). The components of the PCR reaction mixture were from Solis BioDyne (Estonia) and Applied Biosystem (USA).The temperature-time profile of PCR was as follows: Pre-PCR: 95°C for 12 min; PCR (30 cycles): 95°C for 0.5 min, 63°C (rs2928140) or 64°C (for rs2619679 and rs1799796) or 65°C (rs5030789) for 0.5 min, 72°C for 1 min; Post-PCR at 72°C for 5min.The amplification products were digested with restriction enzymes:HinfI (rs2619679),EarI (rs2928140),NlaIII (rs5030789), orAluI (rs1799796) at 37°C for 16 hours. Enzyme inactivation lasted 20 minutes at 65°C forEarI and at 80°C forHinfI,NlaIII, andAluI. The enzymes came from New England BioLabs Inc. DNA fragments were separated in a 3% agarose gel with ethidium bromide for UV visualization. Electrophoresis was performed in 1x TBE buffer (10x TBE: 89 mM Tris, 89 mM boric acid, 2 M EDTA pH 8.0) and 100V. Examples of the obtained restriction patterns are shown in Figure 1.Figure 1
PCR-RFLP genotyping of (a)RAD51 rs2619679 polymorphism; (b)RAD51 rs2928140 polymorphism; (c)RAD51 rs5030789 polymorphism; (d)XRCC3 rs1799796 polymorphism.
(a) (b) (c) (d)


## 2.4. Statistical Analysis

The compatibility of the genotype distribution with the Hardy-Weinberg law in the control group and in study group was checked by theχ2 test. Significance of differences between the distribution of genotypes/alleles in the control and study group was assessed by the χ2 test. The risk of comorbidity of genotypes/alleles with the disease was assessed based on odds ratio (OR) together with a 95% confidence interval. All results were considered statistically significant atp values <0.05. Statistical calculations were made using spreadsheets available on the websites: quantpsy.org/chisq/chisq.htm and vassarstats.net/odds2x2.html.


## 3. Results

Table3 presents results of studied polymorphisms inRAD51 andXRCC3 using the PCR-RFLP method. The distribution of genotypes and alleles in the control group and in patients with prostate cancer was consistent with Hardy-Weinberg law (p>0.05). Statistically significant differences were found in the distribution of genotypes and alleles for rs5030789 and rs1799796 polymorphism inRAD51 andXRCC3, respectively, between control group and prostate cancer patients.Table 3
Distribution of genotypes and allele frequency of studied SNPs inRAD51 and XRCC3 in prostate cancer patients and control group.
Gene rs Genotype/allele Control group (n=205) Prostate cancer patients (n=99) RAD51 rs2619679 TT 48 30 TA 101 51 AA 56 18 χ2 = 3.59, p = 0.17 T 197 111 A 213 87 χ2 = 3.43, p = 0.06 rs2928140 GG 95 43 GC 63 36 CC 47 20 χ2 = 1.00, p = 0.61 G 253 122 C 157 76 χ2 = 0, p = 1.00 rs5030789 AA 29 7 AG 106 45 GG 70 47 χ2 = 6.43, p = 0.04 A 164 59 G 246 139 χ2 = 5.98, p = 0.01  XRCC3 rs1799796 AA 77 28 AG 92 45 GG 36 26 χ2 = 4.15, p = 0.13 A 246 101 G 164 97 χ2 = 4.40, p = 0.04The odds ratio (OR) analysis showed that rs5030789 polymorphism inRAD51 and rs1799796 polymorphism inXRCC3 are associated with susceptibility to prostate cancer (Table 4). The presence of the GG genotype in both polymorphic sites ofRAD51 andXRCC3 increases the risk of prostate cancer (OR = 2.782,p = 0.038 for rs5030789; OR = 1.986,p = 0.041 for rs1799796). Also, the presence of the G allele increases the risk of developing prostate cancer in both above polymorphisms (OR = 1.571 for rs5030789 and OR = 1.441 for rs1799796,p<0.05).Table 4
Prostate cancer risk andRAD51 and XRCC3 polymorphism.
Gene rs Genotype/allele Control group (n=205) Prostate cancer patients (n=99) OR (95% Cl) p value RAD51 rs2619679 TT 48 30 1 (Ref.) TA 101 51 0.808 (0.459-1.424) 0.554 AA 56 18 0.514 (0.255-1.036) 0.089 T 197 111 1 (Ref.) A 213 87 0.725 (0.515-1.020) 0.077 rs2928140 GG 95 43 1 (Ref.) GC 63 36 1.262 (0.732-2.178) 0.484 CC 47 20 0.940 (0.498-1.775) 0.841 G 253 122 1 (Ref.) C 157 76 1.004 (0.708-1.423) 0.526 rs5030789 AA 29 7 1 (Ref.) AG 106 45 1.759 (0.718-4.309) 0.299 GG 70 47 2.782 (1.126-6.872) 0.038 A 164 59 1 (Ref.) G 246 139 1.571 (1.093-2.228) 0.018  XRCC3 rs1799796 AA 77 28 1 (Ref.) AG 92 45 1.345 (0.768-2.356) 0.371 GG 36 26 1.986 (1.022-3.860) 0.041 A 246 101 1 (Ref.) G 164 97 1.441 (1.024-2.027) 0.044Because the polymorphism rs5030789 inRAD51 and polymorphism rs1799796 inXRCC3 increase the risk of prostate cancer, the correlation of these polymorphisms with age and clinicopathological characteristcs of prostate cancer patients was examined (Table 5). It was revealed that there is a relationship between rs1799796 polymorphism inXRCC3 and the age of patients over 71 years (OR = 1.916,p = 0.033) and Gleason score of cancer equal to or higher than 7 (OR = 2.373,p = 0.012). No association was found with the level of PSAT, nor with rs5030789 inRAD51 nor rs1799796 inXRCC3.Table 5
Relationship between G allele for rs5030789 inRAD51 and rs1799796 in XRCC3 and clinicopathological characteristics of prostate cancer patients.
Clinicopathological parameter rs5030789 rs1799796 A G A G Age ≤ 71 35 67 60 42 > 71 24 72 41 55 OR = 1.567 (0.846-2.902) OR = 1.916 (1.089-3.371) p = 0.202 p = 0.033  PSAT (ng/ml) < 4-10 34 68 53 49 > 10 25 71 48 48 OR = 1.420 (0.768-2.624) OR = 1.082 (0.619-1.889) p = 0.335 p = 0.887  Free/total PSA (F/T PSA) < 0.16 25 71 44 52 ≥ 0.16 34 68 57 45 OR = 0.704 (0.381-1.301) OR = 0.668 (0.381-1.170) p = 0.335 p = 0.203  PSA Density (PSAD, ng/ml) < 0.28 26 72 49 49 ≥ 0.28 33 67 52 48 OR = 0.733 (0.397-1.352) OR = 0.923 (0.529-1.612) p = 0.399 p = 0.888  Prostate volume (ml) < 48 31 61 52 40 ≥ 48 28 78 49 57 OR = 1.416 (0.768-2.608) OR = 1.512 (0.862-2.652) p = 0.337 p = 0.192  Gleason score < 7 19 37 37 19 ≥ 7 40 102 64 78 OR = 1.309 (0.675-2.541) OR = 2.373 (1.246-4.521) p = 0.532 p = 0.012  Cancer stage T1-T2 35 81 58 58 T3-T4 24 58 43 39 OR = 1.224 (0.664-2.256) OR = 0.907 (0.515-1.597) p = 0.624 p = 0.841


## 4. Discussion

Prostate specific antigen (PSA) is a blood-based biomarker used for the detection and surveillance of prostate cancer. However, PSA levels can also be affected by benign prostatic hyperplasia (BPH), local inflammation or infection, prostate volume, age, and genetic factors. In this regard, PSA seems to be an organ but not cancer specific biomarker [19]. Seeking the molecular mechanisms underlying prostate cancer, many mutations and polymorphisms of a single nucleotide have been identified, especially in DNA repair genes, which increase the risk of developing prostate cancer. Polymorphic genes of DNA repair are in great part included in low penetrance genes, which means that single gene product most often slightly affects the disease occurrence risk, but accumulation of changed alleles can have essential significance for its development. RAD51, which is a critical protein involved in the homologous recombination repair pathway, interacts with XRCC2, XRCC3, and other proteins to form a complex that is crucial for repairing the double-strand breaks and maintaining chromosome stability [12, 16, 20].To our knowledge, genetic abnormalities in RAD51 paralogs, i.e., RAD51C and RAD51D, have been identified in prostate cancer, but not in RAD51 [5–10]. Our study has shown the importance ofRAD51and its paralogXRCC3 polymorphism in prostate cancer. Single nucleotide polymorphism within these genes may affect DNA double-strand break repair capacity, hence the increased susceptibility to neoplastic transformation. There is growing body of evidence which suggests that polymorphic variants of these genes have impact on developing different cancers. A meta-analysis conducted by Zeng et al. [11] suggests thatRAD51 rs1801320 (135G/C) polymorphism is a risk factor for three common gynecological tumors, i.e., breast, endometrial, and ovarian cancers, and especially for endometrial cancer. Al-Zoubi et al. [21] in their studies demonstrated that the homozygous variant T172T (rs1803121) is significantly associated with breast cancer risk (OR 3.717, 95% CI 2.283-6.052,p < 0.0001), while the heterozygous variant G135C (rs1801320) has no significant relationship with the risk of sporadic breast cancer (OR 1.598, 95% CI 0.5638-4.528,p > 0.05). However, both variants homozygous T172T and heterozygous G135C together showed a significant association with sporadic breast cancer susceptibility. Michalska et al. [22] found that the polymorphism ofRAD51 may be positively associated with the incidence of triple-negative breast carcinoma while Sekhar et al. [23] indicated thatRAD51 135G > C substitution in the homozygous form (CC) increases the risk of breast cancer in an ethnic-specific manner. Söderlund et al. [24] suggest thatRAD51 135G>C polymorphism predicts cyclophosphamide/methotrexate/5-fluorouracil chemotherapy effect in early breast cancer.Polymorphism of theRAD51 also seems to play a role in other types of cancer. In our previous study we found a significant relationship betweenRAD51 polymorphism rsl801320 and an increased risk of prostate cancer [17]. It has been shown that subjects carryingRAD51 rs1801320 GC genotype also have an increased risk of glioblastoma (GC vs GG, χ(2) = 10.75; OR 3.0087;p = 0.0010). In addition,RAD51 rs1801320 C allele increased the risk of developing glioblastoma also in combination with theXRCC1 rs25487 G allele andXRCC3 rs861539 C allele (χ(2) = 6.558;p = 0.0053) [25]. Trang et al. [26] showed that the combination ofHelicobacter pylori infection andRAD51 G135C genotype of the host leads to an increased score for intestinal metaplasia. This suggests thatRAD51 G135C may be an important predictor for gastric cancer ofHelicobacter pylori-infected patients. Mucha et al. [27] study revealed a statistically significant association also between rs5030789 polymorphism inRAD51 and the risk of colorectal cancer. In turn in the case of rs2619679 polymorphism inRAD51, it was shown that it does not correlate with the risk of head and neck cancer [28].Avadanei et al. [29] findings suggest thatXRCC3 polymorphism in hepatocellular carcinoma may affect the aggressiveness of the tumor expressed by tumor grade. Statistically significant differences were shown for rs1799796 A>G and tumor grade, between wild type (AA) and heterozygote (AG) genotypes, and wild type (AA) and heterozygote and homozygote (AG and GG) genotypes. The logistic regression analysis found an OR of rs1799796 polymorphism occurrence in hepatocellular carcinoma related to tumor grade. In the case of rs861539 C>T polymorphism, statistical analysis showed better survival only for the homozygote (TT) compared to the heterozygote (CT) genotype, and in the case of rs1799796 A>G polymorphism, a longer survival for wild type (AA) compared to heterozygote (AG) and to heterozygote and homozygote (AG and GG) genotypes, respectively. The results presented by Ali et al. [30] suggest that the polymorphism rs1799794 inXRCC3 is strongly associated with the development of breast cancer in Saudi women while genotype and allele frequencies of rs861539 C>T and rs1799796 A>G did not show a significant difference. However, the frequency of rs1799796 differed significantly in patients depending on the age of the diagnosis, tumor grade, and ER and HER2 status. The wild type A allele occurred more frequently in the ER- and HER2- group. It was also found that the presence of the polymorphism rs1799796 inXRCC3 may reduce the risk of oral premalignant lesions [31]. On the other hand, Mandal et al. [32] showed no significant association between rs1799796 and rs861539 polymorphism inXRCC3 and the risk of prostate cancer. In the case of studies conducted by Mittal et al. [33], no direct relationship was found between the occurrence of rs1799796 polymorphism inXRCC3 and the incidence of bladder cancer. In addition, the studied polymorphism seems to be not related to the incidence of nasopharyngeal cancer as well as head and neck cancer [27, 34]. However, a meta-analysis of 5302 cases of ovarian cancer compared to 8075 control cases revealed statistically significant correlation of rs1799794 and rs1799796 polymorphism inXRCC3 and an increased risk of developing ovarian cancer in Caucasians, Asian, and African population [35]. It is also worth pointing out that Vral et al. [36] have demonstrated the combined effect of polymorphisms inRAD51 andXRCC3 on breast cancer risk.


## 5. Conclusion

Our study showed that rs5030789 polymorphism inRAD51 and rs1799796 inXRCC3 are associated with the occurrence of prostate cancer in Polish men. We have demonstrated correlation between the rs1799796 polymorphism inXRCC3 and the age of patients over 71 years and Gleason score of tumor higher than 7. Our findings indicate the importance ofRAD51 andXRCC3polymorphisms in the development of prostate cancer. Based on the results presented, we suggest considering genetic testing forRAD51 andXRCC3 to identify those men who have DNA repair deficiency and who have not responded to standard treatment.



---

*Source: 2976373-2019-05-02.xml*